,148 AMG232 is an investigational orally bioavailable selective MDM2 inhibitor, and the combination of AMG232 and pembrolizumab anti-PD-1 treatment reduces IL-6 expression as well as enhances T cell-mediated tumor killing in ovarian cancer cell lines.69 Here, MDM2 is linked to neoplasm.